• ABOUT
  • THE GROUP
  • NEWS & MEDIA
  • EVENTS
  • CAREER
  • CONTACT US
  • 0

SALSA MLPA Reagent Kits for Predisposition to Cancer

More Views

SALSA MLPA Reagent Kits for Predisposition to Cancer
MLPA (Multiplex Ligation-dependant Probe Amplification (MLPA) is a multiplex PCR method that enables the copy number variation (CV) detection of up to 60 DNA sequences in a single reaction. 96 DNA samples can be handled simultaneously with results being available within 24 hours.
Read More
Add to Shortlist

Features & Benefits

  • Predisposition to Cancer
  • Simultaneous Detection of copy number, methylation and known point mutation
  • Low Input - Requires only 50 ng of DNA
  • Reproducible - High concordance with other techniques
  • Time Efficient - Results available within 24 hrs.
  • High Throughput - Can detect up to 60 sequences in 96  DNA samples, in one reactions
  • Cost Effective

Product Details

MLPA® is the gold standard for DNA copy number quantification and is used to study both hereditary disorders and tumours. MLPA can also be applied to investigate the methylation status of DNA sequences. MRC-Holland, the inventor and manufacturer of MLPA, offers 400 different MLPA panels. MLPA (Multiplex Ligation-dependant Probe Amplification (MLPA) is a multiplex PCR method that enables the copy number variation (CV) detection of up to 60 DNA sequences in a single reaction. 96 DNA samples can be handled simultaneously with results being available within 24 hours.


Components provided per SALSA MLPA Reagent Kit  



  • SALSA MLPA Buffer (yellow cap)

  • SALSA Ligase-65 (green cap)

  • Ligase Buffer A (transparent cap)

  • Ligase Buffer B (white cap)

  • SALSA PCR Primer Mix (brown cap)

  • SALSA Polymerase (orange cap) 


MLPA has the following solutions for Blood Cancer:





















































































































































































































































PRODUCT NAME APPLICATION REGION
ME024-9p21 Tumours, Cutaneous melanoma 9p21, CDKN2A, CDKNA2B
P002-BRCA1CE Hereditary breast cancer (BRCA1) BRCA1 17q21.31
P003-MLH1/MSH2CE Lynch Syndrome MLH1 3p22.2, MSH2 2p21
P008-PMS2 Lynch Syndrome PMS2 7p22
P016-VHLCE Von Hippel-Lindau Syndrome VHL, 3p25
P017-MEN1 Multiple endocrine neoplasia MEN1 11q13
P041-ATM-1 Ataxia-Telangiectasia (AT) ATM 11q23
P042-ATM-2 Ataxia-Telangiectasia (AT) ATM 11q23
P043-APC Hereditary Polyposis Colon Cancer APC, 5q21-q22
P044-NF2 Neurofibromatosis type 2 (NF2) NF2 22q12
P045-BRCA2/CHEK2CE Breast cancer, hereditary BRCA2, CHEK2
P046-TSC2 Tuberous Sclerosis TSC2 16p13.3
P047-RB1 Retinoblastoma (RB) RB1 13q14
P056-TP53 Li-Fraumeni syndrome (LFS) and tumour analysis TP53 17p13.1
P057-FANCD2-PALB2 Fanconi anemia (FA) FANCD2. 3p25.3, PALB2 16p12
P067-PTCH Gorlin syndrome PTCH 9q22.3
P072-MSH6 Lynch Syndrome MSH6
P077-BRCA2 Breast cancer, hereditary BRCA2
P081-NF1 mix 1 Neurofibromatosis NF1 17q11.2
P082-NF1 mix 2 Neurofibromatosis NF1 17q11.2
P083-CDH1 Hereditary diffuse gastric cancer CDH1 at 16q22.1
P087-BRCA1 Breast cancer, hereditary BRCA1
P090-BRCA2CE Breast cancer, hereditary BRCA2 13q13.1
P101-STK11 Peutz-Jeghers syndrome (PJS) STK11 19p13.3
P118-WT1 Wilms tumours, WAGR, Denys-Drash, Frasier syndrome. WT1 11p13
P122-NF1-area Neurofibromatosis NF1 17q11.2
P124-TSC1 Tuberous Sclerosis TSC1 9q34
P158-JPS Juvenile polyposis syndrome (JPS) BMPR1A 10q22, SMAD4 18q21, PTEN 10q23
P190-CHEK2 Breast cancer susceptibility CHEK2 22q12, ATM , PTEN, TP53
P215-EXT Multiple Osteochondromas EXT1 8q24, EXT2 11p11
P225-PTEN Cowden syndrome and tumour analysis PTEN 10q23
P226-SDH Paragangliomas (PGL) SDHD 11q23.1, SDHB 1p36.1, SDHC 1q23.3
P239-BRCA1 region Breast cancer BRCA1 region
P240-BRIP1/CHEK1 Hereditary predisposition to Cancer BRIP1 17q22, CHEK1 11q22
P244-AIP-MEN1-CDKN1B Multiple endocrine neoplasia (MEN) AIP 11q13, MEN1 11q13, CDKN1B 12p13
P248-MLH1-MSH2 Confirmation Lynch Syndrome MLH1 3p21.3, MSH2 2p21
P258-SMARCB1 Rhabdoid tumors SMARCB1 22q11.2
P260-PALB2-RAD50-RAD51C-RAD51D Fanconi Anemia 5q31, 16p12, 17q12, 17q22
P308-MET Papillary renal carcinoma, various cancers MET 7q31, PTEN 10q23.31, LRRK2 12q12
P337-TSC2 Tuberous sclerosis TSC2 gene, 16p13.3
P378-MUTYH Colon cancer, stomach cancer (hereditary) 1p34 and 15q13
P417-BAP1 Melanocytic tumours, mesothelioma BAP1, 3p21.1
P419-CDKN2A/2B-CDK4 Familial melanoma CDKN2A, CDKN2B, CDK4, MITF E318K
P429-SDHA-MAX Paraganglioma and pheochromocytoma 5p15.3 and 14q23.3
P437-Familial MDS-AML Familial MDS-AML RUNX1, CEBPA, GATA2, TERT, TERC
P455-LZTR1 Schwannomatosis 22q11.21
P466-CDC73 HPT jaw tumour syndrome, famial hyperparathyroidism, parathyroid carcinoma CDC73



Read More